Method and composition for generating basal forebrain cholinergic neurons (BFCNS)
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
1. A method of generating basal forebrain cholinergic neurons (BFCNs) comprising:
culturing pluripotent stem cells (PSCs) in a basal media comprising an inhibitor of transforming growth factor beta (TGF-β) signaling and an activator of sonic hedgehog (Shh) signaling thereby inducing neuroectodermal differentiation, wherein the inhibitor of TGF-β signaling is SB431542 and LDN193189 and the activator of Shh signaling is smoothened agonist (SAG) and purmorphamine, and
wherein the basal media lacks basic fibroblast growth factor (bFGF), TGF-β, lithium chloride (Li—Cl), GABA and pipecolic acid, thereby generating BFCNs.
2. The method of claim 1 , wherein culturing is performed for a duration of about 4 to 9 days.
3. The method of claim 1 , wherein the inhibitor is present in the culture media from about day 2 to day 8.
4. The method of claim 1 , further comprising selecting for isolating CD271+cells.
5. The method of claim 4 , wherein isolating is performed after about 9 to 12 days of culturing.
6. The method of claim 5 , further comprising culturing the CD271+cells to generate neuronal embryoid bodies (NEBs).
7. The method of claim 6 , wherein the CD271+cells are cultured for about 7 days thereby generating NEBs.
8. The method of claim 7 , further comprising:
a) harvesting the NEBs; and
b) dissociating cells of the NEBs and re-plating the dissociated cells as a monolayer.
9. The method of claim 8 , wherein the re-plated cells are cultured for an additional duration in culture media having growth factors to maintain survival of the cells, and wherein the cells express Tuj1, MAP2, BF1, Nkx2.1 and p75.
10. The method of claim 8 , where the cultured cells exhibit mature action potentials.
11. The method of claim 1 , further comprising culturing the cells to confluence prior to contacting the cells with the activator or inhibitor.
12. The method of claim 1 , wherein the PSCs are human cells.
13. The method of claim 1 , wherein the PSCs are induced pluripotent stem cells (iPSCs).
14. The method of claim 13 , wherein the iPSCs are derived from a subject diagnosed with, or at risk of having Alzheimer's disease (AD).
15. The method of claim 14 , wherein the iPSCs are produced using a BFCN from the subject having a mutation in presenilin 2 (PSEN2).
16. The method of claim 15 , wherein the mutation is PSEN2 N141I.
17. The method of claim 15 , wherein the mutation is repaired after generation of the iPSCs.
18. The method of claim 17 , wherein the mutation is repaired using a gene editing system selected from the group consisting of CRISPR/Cas system, Cre/Lox system, TALEN system and homologous recombination.
19. The method of claim 17 , wherein the cultured cells exhibit a normalization of Aβ42/40 ratio as compared to control.
20. The method of claim 17 , wherein the cultured cells exhibit a reduction in electrophysiological deficit as compared to control.
21. The method of claim 20 , wherein the reduction in electrophysiological deficit comprises restoration of maximal number of spikes and spike height in response to depolarizing current as compared to control.
22. The method of claim 1 , wherein the cultured cells exhibit homogeneous expression of Nkx2.1 by day 8 of culturing.
23. The method of claim 1 , wherein the cultured cells exhibit recordable action potentials by day 8 of culturing.
24. The method of claim 1 , wherein the cultured cells exhibit mature action potentials by day 38 of culturing.